The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Jun 2014
Randomized Controlled Trial Multicenter Study Comparative StudyTrastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician's choice in this population of patients. ⋯ Genentech.